TALi Digital (ASX:TD1) - Outgoing Managing Director & CEO, Glenn Smith
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • TALi Digital (TD1) announces Glenn Smith has resigned as Managing Director and CEO of the company, effective March 31
  • Mr Smith says his decision related to his desire to focus on other priorities
  • The board says it will undertake a search for a new CEO, and in the interim, TALi Digital Chair Sue MacLeman will take on the added responsibility
  • TD1 shares hold steady at 1.1 cents

Digital health company TALi Digital (TD1) has announced Glenn Smith has resigned as Managing Director and CEO of the company, effective March 31.

Mr Smith said his decision related to his desire to focus on other priorities.

“I am exceptionally proud of what my team and I have achieved this far and excited about what the future holds for the business,” said Mr Smith.

“Now is the right time for me to handover to the new executive team and importantly the outlook for the business is extremely positive.”

The board said it will undertake a search for a new CEO, and in the interim, TALi Digital Chair Sue MacLeman will take on the added responsibility.

Mr Smith had been in his role as MD since October 2017 and most recently helped the company raise funds to support the commercialisation and development of TALi products.

He previously had more than 20 years of experience in a variety of senior and executive roles, particularly in start-ups.

TD1 shares were steady at 1.1 cents as of 10:09 am AEDT.

TD1 by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next